Abstract
The development of lymphomas and leukemias is frequently caused by chromosomal translocations that deregulate cellular pathways of differentiation, proliferation or survival. The molecules that are involved in these aberrations provide rational targets for selective drug therapies. Recently, several disease specific translocations have been identified in human MALT lymphoma. These aberrations either upregulate the expression of BCL10 or MALT1 or induce the formation of API2-MALT1 fusion proteins. Genetic and biochemical experiments identified BCL10 and MALT1 as central components of an oligomerization - ubiquitinylation – phosphorylation cascade that activates the transcription factor NF-κB in response to antigen receptor ligation. Deregulation of the signaling cascade is directly associated with antigen independent MALT lymphoma growth. Here we provide an overview of the physiological and pathological functions of BCL10 / MALT1 signal transduction and discuss the potential of this pathway as a drug target.
Keywords: Lymphoma, Malt1, Bcl10, API2-MALT1, NF-κB, antigen receptor, chromosomal translocation, fusion protein
Current Drug Targets
Title: The Bcl10 / Malt1 Signaling Pathway as a Drug Target in Lymphoma
Volume: 7 Issue: 10
Author(s): P. Jost, C. Peschel and J. Ruland
Affiliation:
Keywords: Lymphoma, Malt1, Bcl10, API2-MALT1, NF-κB, antigen receptor, chromosomal translocation, fusion protein
Abstract: The development of lymphomas and leukemias is frequently caused by chromosomal translocations that deregulate cellular pathways of differentiation, proliferation or survival. The molecules that are involved in these aberrations provide rational targets for selective drug therapies. Recently, several disease specific translocations have been identified in human MALT lymphoma. These aberrations either upregulate the expression of BCL10 or MALT1 or induce the formation of API2-MALT1 fusion proteins. Genetic and biochemical experiments identified BCL10 and MALT1 as central components of an oligomerization - ubiquitinylation – phosphorylation cascade that activates the transcription factor NF-κB in response to antigen receptor ligation. Deregulation of the signaling cascade is directly associated with antigen independent MALT lymphoma growth. Here we provide an overview of the physiological and pathological functions of BCL10 / MALT1 signal transduction and discuss the potential of this pathway as a drug target.
Export Options
About this article
Cite this article as:
Jost P., Peschel C. and Ruland J., The Bcl10 / Malt1 Signaling Pathway as a Drug Target in Lymphoma, Current Drug Targets 2006; 7 (10) . https://dx.doi.org/10.2174/138945006778559256
DOI https://dx.doi.org/10.2174/138945006778559256 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Modelling and Measuring Redox Cycling and Cytotoxicity of Quinones
Drug Metabolism Letters Novel Agents in CNS Myeloma Treatment
Central Nervous System Agents in Medicinal Chemistry Optical and Multimodal Peptide-Based Probes for In Vivo Molecular Imaging
Anti-Cancer Agents in Medicinal Chemistry Hypoxia-Inducible Factors and Sphingosine 1-Phosphate Signaling
Anti-Cancer Agents in Medicinal Chemistry Update on Hsp90 Inhibitors in Clinical Trial
Current Topics in Medicinal Chemistry Tumour Re-Differentiation Effect of Retinoic Acid: A Novel Therapeutic Approach for Advanced Thyroid Cancer
Current Pharmaceutical Design Anticancer Agents Derived from Natural Products
Mini-Reviews in Medicinal Chemistry Nanocarriers for Tracking and Treating Diseases
Current Medicinal Chemistry Crohns Targeted Therapy: Myth or Real Goal?
Current Drug Discovery Technologies Histone Deacetylase Inhibitors: From Chromatin Remodeling to Experimental Cancer Therapeutics
Current Medicinal Chemistry Human Immunodeficiency Virus-Induced Apoptosis of Human Breast Cancer Cells Via CXCR4 is Mediated by the Viral Envelope Protein But Does Not Require CD4
Current HIV Research A Case of Ischemic Stroke in Acute Promyelocytic Leukemia at Initial Presentation: Relevance of All-Trans Retinoic Acid Treatment
Cardiovascular & Hematological Disorders-Drug Targets Protocatechuic Acid and Human Disease Prevention: Biological Activities and Molecular Mechanisms
Current Medicinal Chemistry microRNAs: Promising Biomarkers and Therapeutic Targets of Acute Myocardial Ischemia
Current Vascular Pharmacology The Endothelin Axis: A Novel Target for Pharmacotherapy of Female Malignancies
Current Vascular Pharmacology Interleukin-19 as an Immunoregulatory Cytokine
Current Molecular Pharmacology Synthesis of Combretastatin A-4 Analogs and their Biological Activities
Anti-Cancer Agents in Medicinal Chemistry The Hydroxamic Acids as Potential Anticancer and Neuroprotective Agents
Current Medicinal Chemistry T Lymphocytes as Targets of Gene Transfer with Moloney-Type Retroviral Vectors
Current Gene Therapy Pertinence of Apoptosis Markers for the Improvement of In Vitro Fertilization (IVF)
Current Medicinal Chemistry